Please use this identifier to cite or link to this item: http://hdl.handle.net/2067/43180
DC FieldValueLanguage
dc.contributor.authorMiccoli, Andreait
dc.contributor.authorManni, Matteoit
dc.contributor.authorPicchietti, Simonait
dc.contributor.authorScapigliati, Giuseppeit
dc.date.accessioned2021-03-16T14:39:20Z-
dc.date.available2021-03-16T14:39:20Z-
dc.date.issued2021it
dc.identifier.issn2076-393Xit
dc.identifier.urihttp://hdl.handle.net/2067/43180-
dc.description.abstractIn the last three decades, the aquaculture sector has experienced a 527% growth, producing 82 million tons for a first sale value estimated at 250 billion USD. Infectious diseases caused by bacteria, viruses, or parasites are the major causes of mortality and economic losses in commercial aquaculture. Some pathologies, especially those of bacterial origin, can be treated with commercially available drugs, while others are poorly managed. In fact, despite having been recognized as a useful preventive measure, no effective vaccination against many economically relevant diseases exist yet, such as for viral and parasitic infections. The objective of the present review is to provide the reader with an updated perspective on the most significant and innovative vaccine research on three key aquaculture commodities. European sea bass (Dicentrarchus labrax), Nile tilapia (Oreochromis niloticus), and Atlantic salmon (Salmo salar) were chosen because of their economic relevance, geographical distinctiveness, and representativeness of different culture systems. Scientific papers about vaccines against bacterial, viral, and parasitic diseases will be objectively presented; their results critically discussed and compared; and suggestions for future directions given.it
dc.format.mediumELETTRONICOit
dc.language.isoengit
dc.titleState-of-the-Art Vaccine Research for Aquaculture Use: The Case of Three Economically Relevant Fish Speciesit
dc.typearticle*
dc.identifier.doi10.3390/vaccines9020140it
dc.identifier.pmid33578766it
dc.identifier.scopus2-s2.0-85101561086it
dc.identifier.isi000623304100001it
dc.identifier.urlhttps://api.elsevier.com/content/abstract/scopus_id/85101561086it
dc.relation.journalVACCINESit
dc.relation.firstpage1it
dc.relation.lastpage29it
dc.relation.volume9it
dc.relation.issue2it
dc.description.numberofauthors4it
dc.description.internationalnoit
dc.contributor.countryITAit
dc.type.miur262*
item.openairetypearticle-
item.grantfulltextrestricted-
item.languageiso639-1en-
item.fulltextWith Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.journal.journalissn2076-393X-
crisitem.journal.anceE224530-
Appears in Collections:A1. Articolo in rivista
Files in This Item:
File Description SizeFormat Existing users please
vaccines-09-00140-v2.pdf1.52 MBAdobe PDF    Request a copy
Show simple item record

SCOPUSTM   
Citations 10

1
Last Week
1
Last month
1
checked on Sep 17, 2021

Page view(s)

9
Last Week
0
Last month
0
checked on Sep 22, 2021

Google ScholarTM

Check

Altmetric


All documents in the "Unitus Open Access" community are published as open access.
All documents in the community "Prodotti della Ricerca" are restricted access unless otherwise indicated for specific documents